Moderna, Inc. (NASDAQ:MRNAGet Rating) Director Noubar Afeyan sold 10,000 shares of the stock in a transaction on Wednesday, August 3rd. The stock was sold at an average price of $167.99, for a total value of $1,679,900.00. Following the sale, the director now owns 2,467,209 shares of the company's stock, valued at $414,466,439.91. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Noubar Afeyan also recently made the following trade(s):

  • On Wednesday, July 27th, Noubar Afeyan sold 10,000 shares of Moderna stock. The stock was sold at an average price of $161.00, for a total value of $1,610,000.00.
  • On Wednesday, July 20th, Noubar Afeyan sold 10,000 shares of Moderna stock. The stock was sold at an average price of $167.00, for a total transaction of $1,670,000.00.
  • On Wednesday, July 13th, Noubar Afeyan sold 10,000 shares of Moderna stock. The stock was sold at an average price of $168.88, for a total transaction of $1,688,800.00.
  • On Wednesday, July 6th, Noubar Afeyan sold 10,000 shares of Moderna stock. The stock was sold at an average price of $154.85, for a total transaction of $1,548,500.00.
  • On Wednesday, June 29th, Noubar Afeyan sold 10,000 shares of Moderna stock. The stock was sold at an average price of $140.47, for a total transaction of $1,404,700.00.
  • On Wednesday, June 22nd, Noubar Afeyan sold 10,000 shares of Moderna stock. The stock was sold at an average price of $127.69, for a total transaction of $1,276,900.00.
  • On Wednesday, June 8th, Noubar Afeyan sold 10,000 shares of Moderna stock. The shares were sold at an average price of $147.47, for a total value of $1,474,700.00.
  • On Wednesday, June 1st, Noubar Afeyan sold 10,000 shares of Moderna stock. The shares were sold at an average price of $146.31, for a total value of $1,463,100.00.
  • On Wednesday, May 25th, Noubar Afeyan sold 10,000 shares of Moderna stock. The stock was sold at an average price of $130.80, for a total value of $1,308,000.00.
  • On Friday, May 13th, Noubar Afeyan sold 100,000 shares of Moderna stock. The stock was sold at an average price of $134.47, for a total value of $13,447,000.00.

Moderna Price Performance

Ad Legacy Research

MUST WATCH: Unusual 3-second financial maneuver

In 2020, Jeff Clark revealed how to use a unique 3-second transaction…To get Starbucks to pay for his morning coffee.
Now, he’s revealing a new 3-second transaction…

Shares of NASDAQ:MRNA traded down $7.34 during trading on Friday, reaching $186.84. The stock had a trading volume of 5,419,291 shares, compared to its average volume of 6,847,178. Moderna, Inc. has a 52 week low of $115.61 and a 52 week high of $497.49. The business's 50-day moving average price is $152.33 and its 200 day moving average price is $152.85. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.99 and a quick ratio of 1.56. The stock has a market capitalization of $74.32 billion, a PE ratio of 5.69, a P/E/G ratio of 1.05 and a beta of 1.61.

Moderna (NASDAQ:MRNAGet Rating) last posted its earnings results on Wednesday, August 3rd. The company reported $5.24 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $4.73 by $0.51. Moderna had a net margin of 61.12% and a return on equity of 94.76%. The company had revenue of $4.73 billion during the quarter, compared to analysts' expectations of $3.95 billion. During the same quarter in the previous year, the company posted $6.46 earnings per share. Moderna's quarterly revenue was up 8.7% compared to the same quarter last year. As a group, equities analysts predict that Moderna, Inc. will post 27.29 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on MRNA shares. SVB Leerink lifted their target price on Moderna from $70.00 to $77.00 and gave the stock an “underperform” rating in a research report on Monday. Morgan Stanley cut their price target on shares of Moderna from $199.00 to $197.00 and set an “equal weight” rating for the company in a research note on Thursday. Finally, Piper Sandler cut their price target on shares of Moderna from $348.00 to $214.00 and set an “overweight” rating for the company in a research note on Tuesday, May 17th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and three have given a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $226.92.

Institutional Trading of Moderna

Hedge funds and other institutional investors have recently modified their holdings of the stock. Confluence Wealth Services Inc. acquired a new stake in shares of Moderna in the fourth quarter valued at approximately $25,000. Standard Family Office LLC acquired a new stake in shares of Moderna in the fourth quarter valued at approximately $25,000. Total Clarity Wealth Management Inc. acquired a new stake in shares of Moderna in the second quarter valued at approximately $25,000. AllSquare Wealth Management LLC acquired a new stake in shares of Moderna in the first quarter valued at approximately $26,000. Finally, IFS Advisors LLC acquired a new stake in shares of Moderna in the fourth quarter valued at approximately $27,000. Institutional investors and hedge funds own 61.20% of the company's stock.

About Moderna

(Get Rating)

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines.

Further Reading

Cap Expand Partners InsiderTradesChart Noubar Afeyan Sells 10,000 Shares of Moderna, Inc. (NASDAQ:MRNA) Stock Family Offices AND investments

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Before you consider Moderna, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Moderna wasn't on the list.

While Moderna currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here


Cap Expand Partners sharing news from: www.marketbeat.com

Share: